{"nctId":"NCT03063606","briefTitle":"Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Specialist Treatment","startDateStruct":{"date":"2017-09-05","type":"ACTUAL"},"conditions":["Binge-Eating Disorder","Obesity"],"count":31,"armGroups":[{"label":"Cognitive-Behavioral Therapy (CBT)","type":"EXPERIMENTAL","interventionNames":["Behavioral: Cognitive-Behavioral Therapy (CBT)","Drug: NB Medication (on-going from acute treatment)"]},{"label":"Naltrexone/bupropion (NB) (on-going from acute stage)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: NB Medication (on-going from acute treatment)"]}],"interventions":[{"name":"Cognitive-Behavioral Therapy (CBT)","otherNames":[]},{"name":"NB Medication (on-going from acute treatment)","otherNames":["Contrave"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Participated in acute treatment for binge-eating disorder and obesity;\n* Did not have a positive response to acute treatment;\n* Available for the duration of the treatment and follow-up (20 months);\n* Read, comprehend, and write English at a sufficient level to complete study-related materials; and\n* Able to travel to study location (New Haven, CT) for weekly visits.\n\nExclusion Criteria:\n\n* Currently taking anti-depressant medications;\n* Currently taking opioid pain medications or drugs;\n* Currently taking medications that influence eating/weight;\n* History of seizures;\n* Current substance use disorder or other severe psychiatric disturbance (e.g., suicidality);\n* Past or current anorexia nervosa, bulimia nervosa;\n* Pregnant or breastfeeding;\n* Medical status judged by study physician as contraindication.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Binge Eating Frequency (Continuous)","description":"Binge eating assessed by interview and reported as frequency in the past 28 days. Frequency is defined continuously.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"1.6"},{"groupId":"OG001","value":"12.1","spread":"9.9"}]}]}]},{"type":"PRIMARY","title":"Change in Body Mass Index at 4 Months Post-Treatment From Baseline","description":"BMI is calculated using measured height and weight. We report percent of baseline weight. Negative values indicate weight loss. Calculated by value at 4 months minus value at baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.16","spread":"4.27"},{"groupId":"OG001","value":"-1.18","spread":"4.35"}]}]}]},{"type":"SECONDARY","title":"Binge Eating Frequency (Continuous)","description":"Binge eating will be assessed by interview and self-report and the primary outcome is frequency. Frequency will be defined continuously (analyzed dimensionally).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.80","spread":"6.56"},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Binge Eating Frequency (Continuous)","description":"Binge eating will be assessed by interview and self-report and the primary outcome is frequency. Frequency will be defined continuously (analyzed dimensionally).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.70","spread":"2.54"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Body Mass Index","description":"BMI is calculated using measured height and weight (e.g., percent loss).","classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Body Mass Index","description":"BMI is calculated using measured height and weight (e.g., percent loss).","classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":15},"commonTop":["Headache","Diarrhea","Nausea","Constipation","Dry Mouth"]}}}